The MAD Study of SSGJ-613 in Healthy Subjects

Arthritis, Gouty Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalation Phase I Clinical Study of Humanized Monoclonal Antibody Injection (SSGJ-613) in Healthy Adult Chinese Subjects

Status Not yet recruiting

Clinical Trial Summary

To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

Clinical Trial Description

The purposes of this study are to evaluate the safety and tolerability, PK characteristics and immunogenicity of SSGJ-613 after multiple subcutaneous injections in healthy subjects. ;

Study Design

Related Conditions & MeSH terms

Arthritis, Gouty

Clinical Trial Details

NCT number	NCT05966701
Study type	Interventional
Source	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Contact	Qinghong Zhou, BS
Phone	+86 18911301578
Email	zhouqinghong@3sbio.com
Status	Not yet recruiting
Phase	Phase 1
Start date	August 10, 2023
Completion date	March 10, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05119686` - Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 2
Recruiting	`NCT06439602` - Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients	Phase 3
Completed	`NCT00549549` - Celebrex In Acute Gouty Arthritis Study	Phase 3
Active, not recruiting	`NCT05253833` - Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout	Phase 2
Completed	`NCT00663169` - Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout	Phase 2